PDB Entry - 6DCG

(Status - Released)

Summary information:

Title: Discovery of MK-8353: An Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology

PDB DOI: https://doi.org/10.2210/pdb6dcg/pdb

Primary publication DOI: https://doi.org/10.1021/acsmedchemlett.8b00220

Entry authors: Boga, S.B., Deng, Y., Zhu, L., Nan, Y., Cooper, A., Shipps Jr., G.W., Doll, R., Shih, N., Zhu, H., Sun, R., Wang, T., Paliwal, S., Tsui, H., Gao, X., Yao, X., Desai, J., Wang, J., Alhassan, A.B., Kelly, J., Patel, M., Muppalla, K., Gudipati, S., Zhang, L., Buevich, A., Hesk, D., Carr, D., Dayananth, P., Mei, H., Cox, K., Sherborne, B., Hruza, A.W., Xiao, L., Jin, W., Long, B., Liu, G., Taylor, S.A., Kirschmeier, P., Windsor, W.T., Bishop, R., Samatar, A.A.

Initial deposition on: 6 May 2018

Initial release on: 8 August 2018

Latest revision on: 11 October 2023

Downloads:

Structure coordinates (PDBx/mmCIF)

Structure coordinates (PDBML)

Structure coordinates (PDB)

X-ray diffraction data (PDBx/mmCIF)

Validation report (XML)

Validation report (mmCIF)

Validation report (PDF)

Links to more resources for 6DCG at: